No Data
Oppenheimer Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $104
Express News | MoonLake Immunotherapeutics : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $104
MoonLake Immunotherap Initiated at Outperform by Oppenheimer
MoonLake Immunotherap Price Target Announced at $104.00/Share by Oppenheimer
Oppenheimer Initiates Coverage On MoonLake With Outperform Rating, Announces Price Target of $104
Psoriasis Market to Register Incremental Growth by 2034, Predicts DelveInsight | Key Companies - AnaptysBio, Nimbus Lakshmi, Takeda, MoonLake Immunotherapeutics, Bristol-Myers Squibb, Amgen, Dermavant Sciences